Biohit Oyj B Total Liabilities
Biohit Oyj B total liabilities. Based on the latest financial reports, Biohit Oyj B (BIOBV) has total liabilities worth €4.90 Million EUR (≈ $5.73 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of Biohit Oyj B to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Biohit Oyj B (2000–2025)
Total liabilities of Biohit Oyj B from 2000 to 2025. This chart illustrates how Biohit Oyj B's total liabilities have evolved over time, based on quarterly financial data. Check Biohit Oyj B (BIOBV) asset resilience to evaluate the company's liquid asset resilience ratio.
Biohit Oyj B Competitors by Total Liabilities
The table below lists competitors of Biohit Oyj B ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HPP Holdings Bhd
KLSE:0228
|
Malaysia | RM34.38 Million |
|
Korea Ind
KO:002140
|
Korea | ₩143.90 Billion |
|
Allakos Inc
NASDAQ:ALLK
|
USA | $4.08 Million |
|
Pioneer Power Solutions Inc.
NASDAQ:PPSI
|
USA | $6.20 Million |
|
Numulae Gestion de Servicios SOCIMI SA
MC:YNUM
|
Spain | €21.51 Million |
|
Burcelik Bursa Celik Dokum Sanayi AS
IS:BURCE
|
Turkey | TL70.44 Million |
|
Centric Holdings S.A
AT:CENTR
|
Greece | €11.16 Million |
|
Pharmx Technologies Ltd
AU:PHX
|
Australia | AU$2.90 Million |
Liability Composition Analysis (2000–2025)
This chart breaks down Biohit Oyj B's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Biohit Oyj B assets under control.
Liquidity & Leverage Metrics
Biohit Oyj B Total Liabilities Ratios Explained
Biohit Oyj B total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.97 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biohit Oyj B's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biohit Oyj B (2000–2025)
The table below shows the annual total liabilities of Biohit Oyj B from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €4.90 Million ≈ $5.73 Million |
+48.48% |
| 2024-12-31 | €3.30 Million ≈ $3.86 Million |
-5.55% |
| 2023-12-31 | €3.49 Million ≈ $4.08 Million |
-1.77% |
| 2022-12-31 | €3.56 Million ≈ $4.16 Million |
+53.78% |
| 2021-12-31 | €2.31 Million ≈ $2.70 Million |
+11.52% |
| 2020-12-31 | €2.07 Million ≈ $2.42 Million |
-25.72% |
| 2019-12-31 | €2.79 Million ≈ $3.26 Million |
+39.95% |
| 2018-12-31 | €2.00 Million ≈ $2.33 Million |
+20.76% |
| 2017-12-31 | €1.65 Million ≈ $1.93 Million |
-26.22% |
| 2016-12-31 | €2.24 Million ≈ $2.62 Million |
+57.90% |
| 2015-12-31 | €1.42 Million ≈ $1.66 Million |
-22.56% |
| 2014-12-31 | €1.83 Million ≈ $2.14 Million |
-68.71% |
| 2013-12-31 | €5.85 Million ≈ $6.84 Million |
+29.61% |
| 2012-12-31 | €4.51 Million ≈ $5.28 Million |
-75.76% |
| 2011-12-31 | €18.63 Million ≈ $21.78 Million |
+13.71% |
| 2010-12-31 | €16.38 Million ≈ $19.15 Million |
+11.81% |
| 2009-12-31 | €14.65 Million ≈ $17.13 Million |
+0.24% |
| 2008-12-31 | €14.62 Million ≈ $17.09 Million |
-5.69% |
| 2007-12-31 | €15.50 Million ≈ $18.12 Million |
+11.44% |
| 2006-12-31 | €13.90 Million ≈ $16.26 Million |
+2.24% |
| 2005-12-31 | €13.60 Million ≈ $15.90 Million |
+57.78% |
| 2004-12-31 | €8.62 Million ≈ $10.08 Million |
+10.88% |
| 2003-12-31 | €7.77 Million ≈ $9.09 Million |
+3.41% |
| 2002-12-31 | €7.52 Million ≈ $8.79 Million |
-13.20% |
| 2001-12-31 | €8.66 Million ≈ $10.13 Million |
-82.10% |
| 2000-12-31 | €48.39 Million ≈ $56.58 Million |
-- |
About Biohit Oyj B
Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company's diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist … Read more